Priluck I A, Robertson D M, Pritchard D J, Ilstrup D M
Am J Ophthalmol. 1979 Feb;87(2):215-20. doi: 10.1016/0002-9394(79)90146-6.
We studied selective in vivo and in vitro immunologic factors of 25 patients with choroidal malignant melanoma. Immune profile factors did not show consistent differences between patients with melanoma and an age-matched control population. The studies were also non-contributory in delineating variations in immunocompetence with respect to melanoma cell types. Serial immune profiles failed to identify a change when clinical evidence of metastasis developed. When tested as a group, patients with melanoma in whom metastatic disease developed during the study showed significant depression of initial mitogen-induced lymphocyte blastogenesis. This depression was noted in advance of clinically recognized metastatic disease. This group had a wide range of responses that overlapped those of control patients, thus making the usefulness of these testing factors questionable for individual prognosis or for clinical monitoring.
我们研究了25例脉络膜恶性黑色素瘤患者体内和体外的选择性免疫因素。免疫特征因素在黑色素瘤患者与年龄匹配的对照人群之间未显示出一致的差异。这些研究在描绘免疫能力相对于黑色素瘤细胞类型的变化方面也没有提供有用信息。当出现转移的临床证据时，连续的免疫特征未能识别出变化。作为一个整体进行检测时，在研究期间发生转移性疾病的黑色素瘤患者显示出初始丝裂原诱导的淋巴细胞增殖显著降低。这种降低在临床公认的转移性疾病出现之前就已被注意到。该组患者的反应范围很广，与对照患者的反应有重叠，因此这些检测因素对于个体预后或临床监测的实用性存疑。
